Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron
Jeffrey Vacirca, Ali McBride(University of Arizona), George Calcanes, Michael Mosier, Dennis L. Caruana(Yale University), Ralph V. Boccia(Center for Cancer and Blood Disorders)
Cited by 10
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
|The Lancet Oncology|2013|387